Boston Scientific Corporation logo
Boston Scientific Corporation (BSX)
Compare

Boston Scientific Corporation (BSX) PB Ratio: 2.71

Is Boston Scientific Corporation’s P/B ratio high or low?

Boston Scientific Corporation's P/B ratio of 2.71 is 44% below its 5-year average of 4.83, near the low end of its 5-year range (2.70–7.63).

51.14% below its 12-month average of 5.55.

BSX PB Ratio Chart

BSX PB Ratio
2.71-60.26% 1Y
Zoom

BSX Average PB Ratio Chart

BSX Current vs Average PB Ratio Chart

BSX PB Ratio Metrics

PB RATIO

2.71

PB RATIO AVG TTM

5.55

PB RATIO AVG 3Y

5.55

PB RATIO AVG 5Y

4.83

PB RATIO AVG 10Y

4.98

PB RATIO AVG 15Y

4.07

PB RATIO AVG 20Y

3.35

CURRENT VS TTM AVG

-51.14%

CURRENT VS 3Y AVG

-51.20%

CURRENT VS 5Y AVG

-43.86%

CURRENT VS 10Y AVG

-45.60%

CURRENT VS 15Y AVG

-33.48%

CURRENT VS 20Y AVG

-19.16%

BSX Competitors' PB Ratio

NAMEMARKET CAPPB RATIOTTM3Y5Y
Boston Scientific Corporation (BSX)$69.74B2.715.555.554.83
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$62.78B2.112.353.213.54
Cigna Corporation (CI)vs ›$77.02B1.841.872.041.94
Cencora, Inc. (COR)vs ›$54.76B16.1836.3168.07114.95
Cardinal Health, Inc. (CAH)vs ›$53.55BN/A10.9810.127.19
Elevance Health Inc. (ELV)vs ›$86.74B2.021.722.372.67
Becton, Dickinson and Company (BDX)vs ›$52.72B1.691.731.972.09
HCA Healthcare, Inc. (HCA)vs ›$88.05BN/A218.83218.83218.83
Humana Inc. (HUM)vs ›$45.03B2.471.652.302.91
IDEXX Laboratories, Inc. (IDXX)vs ›$44.83B29.5532.9530.6445.11

P/B vs. its own history

At 2.71, P/B is in its normal range, sitting higher than 41% of its 20-year history.

20-year low

0.52

median

3.50

20-year high

7.63

cheaperricher

Book Value Analysis

P/B Ratio

2.71

Market Price / Book Value per Share

Boston Scientific Corporation PB Ratio Formula & Definition

PB Ratio = Market Cap / Total Shareholders' Equity

The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Boston Scientific Corporation PB Ratio FAQ

What is the P/B ratio for Boston Scientific Corporation (BSX)?
The P/B ratio for BSX stock is 2.71.
Is Boston Scientific Corporation's P/B ratio high or low?
Boston Scientific Corporation's P/B ratio of 2.71 is 44% below its 5-year average of 4.83, near the low end of its 5-year range (2.70–7.63).
What is the TTM average P/B ratio for Boston Scientific Corporation (BSX)?
The TTM average P/B ratio for BSX stock is 5.55.
What is the 3Y average P/B ratio for Boston Scientific Corporation (BSX)?
The 3Y average P/B ratio for BSX stock is 5.55.
What is the 5Y average P/B ratio for Boston Scientific Corporation (BSX)?
The 5Y average P/B ratio for BSX stock is 4.83.
What is the 10Y average P/B ratio for Boston Scientific Corporation (BSX)?
The 10Y average P/B ratio for BSX stock is 4.98.
What is the 15Y average P/B ratio for Boston Scientific Corporation (BSX)?
The 15Y average P/B ratio for BSX stock is 4.07.
What is the 20Y average P/B ratio for Boston Scientific Corporation (BSX)?
The 20Y average P/B ratio for BSX stock is 3.35.

Boston Scientific Corporation PB Ratio History

DATEPB RATIO
2026-06-162.71
2026-06-152.70
2026-06-122.71
2026-06-112.73
2026-06-102.79
2026-06-092.83
2026-06-082.81
2026-06-052.81
2026-06-042.82
2026-06-032.76
2026-06-022.76
2026-06-012.77
2026-05-292.79
2026-05-282.84
2026-05-272.92
2026-05-263.33
2026-05-223.34
2026-05-213.30
2026-05-203.28
2026-05-193.28
2026-05-183.23
2026-05-153.05
2026-05-143.10
2026-05-133.07
2026-05-123.13
2026-05-113.08
2026-05-083.12
2026-05-073.27
2026-05-063.24
2026-05-053.24
2026-05-043.29
2026-05-013.27
2026-04-303.33
2026-04-293.30
2026-04-283.38
2026-04-273.47
2026-04-243.59
2026-04-233.80
2026-04-223.75
2026-04-213.44
2026-04-203.53
2026-04-173.71
2026-04-163.67
2026-04-153.73
2026-04-143.69
2026-04-133.65
2026-04-103.57
2026-04-093.54
2026-04-083.62
2026-04-073.58
2026-04-063.62
2026-04-023.63
2026-04-013.58
2026-03-313.63
2026-03-303.64
2026-03-274.27
2026-03-264.33
2026-03-254.31
2026-03-244.21
2026-03-234.29
2026-03-204.29
2026-03-194.31
2026-03-184.40
2026-03-174.39
2026-03-164.31
2026-03-134.27
2026-03-124.23
2026-03-114.30
2026-03-104.32
2026-03-094.44
2026-03-064.40
2026-03-054.51
2026-03-044.46
2026-03-034.56
2026-03-024.70
2026-02-274.74
2026-02-264.68
2026-02-254.54
2026-02-244.64
2026-02-234.59
2026-02-204.60
2026-02-194.67
2026-02-184.71
2026-02-174.71
2026-02-134.78
2026-02-124.74
2026-02-114.70
2026-02-104.75
2026-02-094.74
2026-02-064.88
2026-02-054.96
2026-02-044.83
2026-02-035.86
2026-02-025.87
2026-01-305.98
2026-01-295.90
2026-01-286.00
2026-01-275.98
2026-01-265.98
2026-01-235.91
2026-01-225.84
2026-01-215.86
2026-01-205.83
2026-01-165.63
2026-01-155.76
2026-01-145.99
2026-01-136.02
2026-01-126.12
2026-01-096.24
2026-01-086.29
2026-01-076.31
2026-01-066.25
2026-01-056.10
2026-01-026.05
2025-12-316.10
2025-12-306.14
2025-12-296.12
2025-12-266.14
2025-12-246.15
2025-12-236.14
2025-12-226.16
2025-12-196.11
2025-12-186.14
2025-12-176.04
2025-12-165.94
2025-12-155.89
2025-12-125.92
2025-12-115.87
2025-12-105.93
2025-12-095.91
2025-12-086.00
2025-12-056.23
2025-12-046.25
2025-12-036.30
2025-12-026.33
2025-12-016.46
2025-11-286.49
2025-11-266.45
2025-11-256.48
2025-11-246.27
2025-11-216.19
2025-11-206.18
2025-11-196.20
2025-11-186.34
2025-11-176.50
2025-11-146.56
2025-11-136.71
2025-11-126.66
2025-11-116.55
2025-11-106.45
2025-11-076.39
2025-11-066.33
2025-11-056.32
2025-11-046.32
2025-11-036.30
2025-10-316.71
2025-10-306.70
2025-10-296.68
2025-10-286.73
2025-10-276.82
2025-10-246.74
2025-10-236.82
2025-10-226.92
2025-10-216.65
2025-10-206.70
2025-10-176.61
2025-10-166.51
2025-10-156.51
2025-10-146.41
2025-10-136.32
2025-10-106.36
2025-10-096.48
2025-10-086.45
2025-10-076.39
2025-10-066.44
2025-10-036.48
2025-10-026.41
2025-10-016.38
2025-09-306.50
2025-09-296.46
2025-09-266.54
2025-09-256.54
2025-09-246.53
2025-09-236.51
2025-09-226.46
2025-09-196.52
2025-09-186.54
2025-09-176.56
2025-09-166.59
2025-09-156.65
2025-09-126.84
2025-09-116.95
2025-09-107.01
2025-09-097.20
2025-09-087.20
2025-09-057.14
2025-09-047.15
2025-09-037.16
2025-09-027.10
2025-08-297.03
2025-08-287.04
2025-08-277.05
2025-08-267.09
2025-08-257.00
2025-08-227.07
2025-08-217.01
2025-08-207.06
2025-08-196.91
2025-08-186.86
2025-08-156.87
2025-08-146.94
2025-08-136.83
2025-08-126.84
2025-08-116.84
2025-08-086.87
2025-08-076.86
2025-08-066.86
2025-08-056.98
2025-08-047.11
2025-08-017.02
2025-07-317.05
2025-07-307.18
2025-07-297.16
2025-07-287.11
2025-07-257.13
2025-07-247.14
2025-07-237.24
2025-07-226.93
2025-07-216.98
2025-07-186.97
2025-07-177.03
2025-07-166.94
2025-07-156.96
2025-07-147.01
2025-07-116.94
2025-07-106.98
2025-07-096.92
2025-07-086.88
2025-07-076.98
2025-07-037.01
2025-07-026.97
2025-07-017.04
2025-06-307.22
2025-06-277.16
2025-06-267.03
2025-06-257.01
2025-06-247.00
2025-06-236.88
2025-06-206.81
2025-06-186.81
2025-06-176.84
2025-06-166.82
2025-06-136.70
2025-06-126.63
2025-06-116.68
2025-06-106.68
2025-06-096.72
2025-06-066.86
2025-06-056.91
2025-06-046.89

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
53,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Michael F. Mahoney